This site makes use of Javascript, please enable your web browser to allow Javascript. Thank you.

Kaye Scholer Represents Novartis in Admune Acquisition

October 27, 2015

Kaye Scholer Represents Novartis in Admune Acquisition

Kaye Scholer advised longtime client Novartis in its acquisition of Admune Therapeutics, a Massachusetts-based clinical stage biotechnology company. The deal, announced October 21, broadens Novartis’ immuno-oncology pipeline. Terms of the deal were not disclosed.

With products available in more than 180 countries around the world, Basel, Switzerland-headquartered Novartis is the only global company with leading positions in innovative medicines, eye care and cost-saving generic pharmaceuticals.

The Kaye Scholer team for this transaction included Corporate partner Thomas Yadlon, counsel Aaron Gardner and associates Eric Levine, Christopher Konieczny and Michelle Han; Tax partner Laurie Abramowitz and associate Sarah Soloveichik; and Executive Compensation partner Jeff London and associate Brian Witkowski.

» Read the Novartis press release.

Also of Interest